Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides

Patent 6017523 Issued on January 25, 2000. Estimated Expiration Date:

January 25, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Recombinant DNA encoding novel family of primate hematopoietic growth factors
Patent #: 4877729
Issued on: 10/31/1989
Inventor: Clark, et al.

Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
Patent #: 4959455
Issued on: 09/25/1990
Inventor: Clark, et al.

Method of inducing leukocytosis with a combination of IL-3 and GM-CSF
Patent #: 5032395
Issued on: 07/16/1991
Inventor: Clark, et al.

Cysteine added variants of interleukin-3 and chemical modifications thereof
Patent #: 5166322
Issued on: 11/24/1992
Inventor: Shaw, et al.

Human Interleukin-3(Il-3) variants and their use to promote or antagonize IL-3-mediated processes
Patent #: 5591427
Issued on: 01/07/1997
Inventor: Vadas, et al.

Interleukin-3 (IL-3) mutant polypeptides and their recombinant production Patent #: 5677149
Issued on: 10/14/1997
Inventor: Bauer, et al.

Inventors

Assignee

G.D. Searle & Co.

Application

No. 471039 filed on 06/06/1995

US Classes:

424/85.2, Interleukin930/141Interleukin

Examiners

Primary: Fitzgerald, David L.

Attorney, Agent or Firm

Bennett; Dennis A.

Foreign Patent References

275598 EP 07/19/1988
413383 EP 02/19/1991
3/236400 JP 10/19/1991
4/63595 JP 02/19/1992
2210883 GB 06/19/1989
88/00598 WO 01/19/1988
88/04691 WO 06/19/1988
88/05469 WO 07/19/1988
88/06161 WO 08/19/1988
90/01039 WO 02/19/1990
90/10705 WO 09/19/1990
90/12874 WO 11/19/1990
91/00350 WO 01/19/1991
91/02754 WO 03/19/1991
93/07171-A1 WO. 04/19/1993

International Classes

A61K 038/20
C12N 015/24
C07K 014/54

Abstract

The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain one to three amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (corresponding to residues 119 to 133) have been deleted from the C-terminus, and which also contain one to three amino acid substitutions in the polypeptide. These hIL-3 mutant polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.

Other References

Yang et al, in Cell 47:3 (1986)
Dorsers et al, Gene 55:115 (1987)
Phillips et al, Gene, 84, 501 (1989)
Clark-Lewis et al, Science 231:134 (1986)
Clark-Lewis et al, Proc.Nat.Acad.Sci.USA 85:7897 (1988)
Lokker et al, J. Biol. Chem., 266 (16):10624 (1991)
Clark-Lewis et al, Immune Regulation by Characterized Polypeptides, Alan R. Liss, Inc. (1987) pp. 323-334
Ihle et al, J. Immunol. 126:2184 (1981)
Fung et al, Nature, 307, 233 (1984)
Yokota et al, Proc.Nat.Acad.Sci. USA 81:1070 (1984)
Dorssers et al, J.Biol.Chem 266 (31):21310 (1991)
Koshansky et al, J.Clin.Invest, 90:1879 (1992)
Lopez et al, Proc.Natl.Acad.Sci. USA 89:11842-11846 (1992)
Lokker et al, The EMBO Jour. 10:2125-2131 (1991